Key result
Letter examines metformin cost-effectiveness in DPP and outlines data sharing policies.
Answers are grounded in this paper and cite their sources.
Commentary highlights protocol transparency in Diabetes Prevention Program cohorts, indicating open access for metformin and lifestyle intervention assessments.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Herman et al. (2024) reported a letter. This letter comments on the cost-effectiveness of metformin in the Diabetes Prevention Program 3-year trial and outlines data sharing policies.
Synapse has enriched 10 related papers. Consider them for comparative context: